Quantcast
 
Read Larry Connors' blogShort Term Trading Strategies


 

FDA Panel Warns Against Painkillers

Wed. July 01, 2009; Posted: 12:43 PM
Stocks RSS
(RTTNews) - Tuesday, a panel of outside advisors to the U.S. Food and Drug Administration, or FDA, voted 21-17 in favor of a ban on painkillers Vicodin and Percocet, as they combine Acetaminophen or APAP with a narcotic. The panel also simultaneously voted 21-16 to reduce the dosage of over-the-counter, or OTC painkillers that contain acetaminophen, like Tylenol.

For years, Tylenol has been the staple drug to pop to relieve fever, and ease headaches and body pain. The advisory panel urged lowering doses of Johnson & Johnson's (JNJ | Quote | Chart | News | PowerRating) Tylenol, including selling the extra-strength version by prescription only.

The drug Acetaminophen is used in many painkillers to relieve pain and fever. Prolonged use, over dosage, and abuse of medications containing Acetaminophen lead to liver anomalies and in extreme cases death.

Between 1990 and 2001, Acetaminophen overdose was linked to 458 deaths, 26,000 hospitalizations and 56,000 emergency-room visits annually, according to an internal agency report.

The FDA is not required to follow the panel's recommendations, but generally does so.

The FDA warned that side effects of Acetaminophen will rise when the drug is already in action inside the body, and another drug containing APAP is consumed. Increased alcohol consumption, three or more drinks every day, also raises the risk of liver failure.

Prescription drugs Vicodin, sold by Abbott Laboratories (ABT | Quote | Chart | News | PowerRating), and Percocet, marketed by Endo Pharmaceuticals, are highly popular in the U.S. These analgesics, of which generic versions are also sold, are generally taken to ease moderate and chronic pain, especially for osteoarthritis.

The panel has recommended that the drugs carry a black box warning, the most serious safety label available, if the drugs stay on the market and are not removed from store shelves.

The advisory panel has also recommended that people take less than 4,000 milligrams of Tylenol or other over-the-counter products containing APAP in a day, and only 650 milligrams, or two Regular Strength tablets, at one time. The usual dose is two 500-milligram Extra Strength tablets.

The FDA may not follow the recommended ban on Vicodin or Percocet, as it would lead consumers to switch to other drugs that are more harmful. The FDA may impose more strict regulations in labeling and promote customer consciousness about the hazards Acetaminophen in combination drugs.

Increased awareness about drug abuse and the harmful effects of drug overdose has led biotechnology companies to develop other methods tackle these issues.

BioElectronics Corp. (BIEL.PK), a maker of inexpensive, disposable drug-free anti-inflammatory devices, has come up with PEMF, or portable electromagnetic field, therapy that is a safe and effective alternative for many musculoskeletal disorders. PEMF has demonstrated effectiveness in speeding surgical recovery and in reducing, or completely eliminating, the amount of pain medication required.

Acura Pharmaceuticals Inc. (ACUR | Quote | Chart | News | PowerRating) has taken an alternative route in combating drug abuse by developing Acurox, an immediate release opioid analgesic that is designed to deter misuse and abuse by intentional swallowing of excess quantities of tablets, intravenous injection of dissolved tablets and nasal snorting of crushed tablets. The drug is currently under priority review with the FDA.

For comments and feedback: contact editorial@rttnews.com Copyright(c) 2009 RTTNews.com, Inc. All Rights Reserved

    


More News:   Market Updates | Stock Alerts | All Trading News | Stock Index

Email
Print
Archives
Feedback
Email Article Link
Close X
Recipients email address
Your name
Your email
Add a note (optional)




Stocks RSS





Most Popular News
  UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
* Attendance is strictly limited and are filled on a first-come, first-served basis.
PREMIER SPONSORED LINKS
TRADE CENTER
 
The TradingMarkets Directory
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

© Copyright 2009 The Connors Group, Inc.


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2009 The Connors Group, Inc.